Post-CA Neuroprotection With Magnesium
NCT06455514
Summary
The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.
Eligibility
Inclusion Criteria: * Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved \<2 hours prior to recruitment Exclusion Criteria: * Age \< 18 years or \> 85 years * Traumatic cardiac arrests * Unsustained ROSC (\<20 minutes) * Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC * Plan for withdrawal of life support within 72 hours of ROSC * Known pregnant women at the time of the cardiac arrest * Known prisoners at the time of the cardiac arrest * Subjects who have a medical o social condition that would make them inappropriate for the study based on the PI's or clinical team judgement.
Conditions3
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06455514